EIF2AK3 and prion disease: These studies highlight two critical points: (1) PERK activation leads to phosphorylation of eIF2α and subsequent inactivation of eIF2α occurs downstream to PrPSc replication in the prion diseased mice; and (2) reversing the translational repression of the synaptic proteins is a valid therapeutic strategy for prion disease.